Cobra Biomanufacturing announces an agreement with Debiopharm, a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNF Kinoid
Cobra Biomanufacturing announces an agreement with Debiopharm, a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNF alpha kinoid.
The agreement includes process development and supply of material for clinical trials.
The new agreement replaces a prior manufacturing deal with Neovacs, which has licensed the programme to Debiopharm.
David Thatcher, CEO of Cobra, said: "We are pleased to continue with the process development aspect of the TNF alpha kinoid project while forging a new relationship with Debiopharm".
"This agreement recognises Cobra's previous success in this project and our expertise in producing therapeutic protein vaccines".
Cobra Biomanufacturing is a manufacturer of biopharmaceuticals to the life science industry.
Founded in 1992, Cobra provides innovative manufacturing to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.
TNF kinoid: overproduction of protein cytokines such as TNF alpha is the cause of many inflammatory diseases, such as cancer cachexia and autoimmune diseases.
The TNF alpha kinoid consists of inactivated cytokines, conjugated to a carrier and serves as an active immunisation therapy.
The kinoid treatment induces a potent antibody response by the patient's immune system which neutralises the harmful effects of cytokine overproduction.
Founded in 1979 in Lausanne, Switzerland, Debiopharm is an experienced and competent drug development company that in-licenses compounds with promising in-vivo results to develop for global registration and to out-license to sales and marketing pharmaceutical partners.
Debiopharm is part of an established group of five complementary and synergistic companies, namely Debiovision in Canada, Debioinnovation and Debio RP in Switzerland and Debioclinic in France.
Together, they provide drug development expertise and know-how from the evaluation of early-stage and innovative research, partnering, financing, pre-clinical and clinical trials, to manufacturing and sophisticated drug-delivery systems.
Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin, one of Sanofi-Aventis's leading marketed products; Decapeptyl, the leading product of Ipsen; and Trelstar (1-and 3-month), marketed by Watson Pharmaceuticals.
